Thanks to a successful business model, BioGaia has been able to grow globally with a lean, efficient and agile organization. The business model will also be a key enabler for BioGaia’s ongoing expansion. BioGaia’s business model is based on three external networks – research, production and distribution.
In the research area there are collaborations with more than 50 research institutions and clinics.
The products are manufactured and packaged at six different facilities in Europe and the USA. Trough close and long-term collaboration, it is possible to continuously optimize production and logistic. The suppliers – above all the subsidiary BioGaia Production – are also important partners for product development, both in creating new products and enhancing existing ones.
The distribution network consists of around 60 partners with sales in some 90 countries. Most of these companies have sales representatives who visit doctors and other healthcare professionals. By informing them about the published results of clinical studies, the representatives create interest, knowledge and confidence among doctors who then recommend the products to their patients, who in turn buy the products in pharmacies and similar sales outlets. BioGaia’s products are available at drug stores and pharmacies around the world.
To date, 184 clinical studies using BioGaia’s human strains of Lactobacillus reuteri have been performed on 15,500 individuals of all ages.Read more
BioGaia has a strong network of distribution partners around the globe. Most of the around 80 partners are pharmaceutical or other health companies.Read more
BioGaia’s products are sold in around 100 countries. The largest segment is paediatrics, accounting for over 80 per cent of total sales.Read more